AAS
HOWL icon

Avantax Advisory Services’s Werewolf Therapeutics HOWL Stock Holding History

Avantax Advisory Services’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$11.1K Buy
+10,200
New +$10.5K ﹤0.01% 2353

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Avantax Advisory Services's HOWL Position: Q2 2025 in Review

Avantax Advisory Services opened a new position in Werewolf Therapeutics (HOWL) in Q2 2025: 10,200 shares worth $11.1K. The stake represents ﹤0.01% of the portfolio and ranks #2353 among its holdings.

65 funds tracked by Wall St. Rank hold HOWL as of Q2 2025.

  • Avantax Advisory Services held 10,200 shares of Werewolf Therapeutics worth $11.1K as of Q2 2025.
  • Werewolf Therapeutics was a new Avantax Advisory Services position in Q2 2025.
  • Werewolf Therapeutics made up ﹤0.01% of Avantax Advisory Services's portfolio in Q2 2025, its #2353 holding.
  • 65 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2025.

Based on Avantax Advisory Services's 13F filing for Q2 2025, filed 8 Aug 2025.